Literature DB >> 16832228

Dioxin exposure and benign prostatic hyperplasia.

Amit Gupta1, Arnold Schecter, Corinne C Aragaki, Claus G Roehrborn.   

Abstract

OBJECTIVE: Dioxins decrease prostate weight, reduce androgen responsiveness, and inhibit prostate morphogenesis in rats. We assessed the association of dioxins and benign prostatic hyperplasia (BPH) in participants in the National Health and Nutritional Examination Survey 1999-2000.
METHODS: Forty-two participants were classified as having BPH and 99 were classified as controls. Dioxin exposure was expressed as dioxin toxic equivalents (TEQ). Age, body mass index, waist circumference, race/ethnicity, smoking, physical activity, and education were assessed as potential confounders.
RESULTS: After age adjustment, men without BPH had 20.9% higher TEQs (95% confidence interval [CI] = 5.4-38.7%) as compared with men with BPH. On weighted, multivariate, logistic regression analyses, men with higher dioxin levels had lower odds of having BPH (odds ratio = 0.22, 95% CI = 0.08-0.62).
CONCLUSIONS: Dioxin exposure in the general population may be associated with decreased odds of BPH. Our study findings need to be confirmed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16832228     DOI: 10.1097/01.jom.0000205417.12621.17

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  8 in total

Review 1.  Potential protective mechanisms of aryl hydrocarbon receptor (AHR) signaling in benign prostatic hyperplasia.

Authors:  Vatsal Mehta; Chad M Vezina
Journal:  Differentiation       Date:  2011 Nov-Dec       Impact factor: 3.880

Review 2.  Actions of estrogens and endocrine disrupting chemicals on human prostate stem/progenitor cells and prostate cancer risk.

Authors:  Wen-Yang Hu; Guang-Bin Shi; Dan-Ping Hu; Jason L Nelles; Gail S Prins
Journal:  Mol Cell Endocrinol       Date:  2011-09-05       Impact factor: 4.102

3.  In Utero and Lactational TCDD Exposure Increases Susceptibility to Lower Urinary Tract Dysfunction in Adulthood.

Authors:  William A Ricke; Calvin W Lee; Tyler R Clapper; Andrew J Schneider; Robert W Moore; Kimberly P Keil; Lisa L Abler; Jalissa L Wynder; Arnaldo López Alvarado; Isaac Beaubrun; Jenny Vo; Tyler M Bauman; Emily A Ricke; Richard E Peterson; Chad M Vezina
Journal:  Toxicol Sci       Date:  2016-02-09       Impact factor: 4.849

Review 4.  AHR signaling in prostate growth, morphogenesis, and disease.

Authors:  Chad M Vezina; Tien-Min Lin; Richard E Peterson
Journal:  Biochem Pharmacol       Date:  2008-10-14       Impact factor: 5.858

5.  Inhibition of constitutive aryl hydrocarbon receptor (AhR) signaling attenuates androgen independent signaling and growth in (C4-2) prostate cancer cells.

Authors:  Cindy Tran; Oliver Richmond; Latayia Aaron; Joann B Powell
Journal:  Biochem Pharmacol       Date:  2012-12-22       Impact factor: 5.858

6.  Synthesis and biological evaluation of FICZ analogues as agonists of aryl hydrocarbon receptor.

Authors:  Hao Wu; Binkai Liu; Ka Yang; Gabrielle N Winston-McPherson; Eric D Leisten; Chad M Vezina; William A Ricke; Richard E Peterson; Weiping Tang
Journal:  Bioorg Med Chem Lett       Date:  2020-01-07       Impact factor: 2.823

7.  Serum dioxin, testosterone, and subsequent risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans.

Authors:  Amit Gupta; Norma Ketchum; Claus G Roehrborn; Arnold Schecter; Corinne C Aragaki; Joel E Michalek
Journal:  Environ Health Perspect       Date:  2006-11       Impact factor: 9.031

8.  The AhR Ligand, TCDD, Regulates Androgen Receptor Activity Differently in Androgen-Sensitive versus Castration-Resistant Human Prostate Cancer Cells.

Authors:  Maryam Ghotbaddini; Joann B Powell
Journal:  Int J Environ Res Public Health       Date:  2015-07-06       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.